A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
The purpose of this study is to compare the efficacy and safety of BMS-986393 versus standard regimens in adult participants with Relapsed or Refractory and Lanalidomide-refractory Multiple Myeloma.
Relapsed or Refractory Multiple Myeloma (RRMM)
DRUG: BMS-986393|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Daratumumab|DRUG: Pomalidomide|DRUG: Dexamethasone|DRUG: Carfilzomib
Progression Free Survival (PFS), Up to 5 years after the last participant is randomized|Minimal residual disease (MRD)-negativity in complete response (CR), Up to 1 year after the last participant is randomized
Overall survival (OS), Up to 5 years after the last participant is randomized|Overall response rate (ORR), Up to 5 years after the last participant is randomized|Minimal residual disease (MRD)-negative status, Up to 5 years after the last participant is randomized|Complete response rate (CRR), Up to 5 years after the last participant is randomized|Time to response (TTR), Up to 5 years after the last participant is randomized|Duration of response (DOR), Up to 5 years after the last participant is randomized|The proportion of participants with adverse events (AEs), Up to 5 years after the last participant is randomized|The proportion of participants with adverse events of special interest (AESI), Up to 5 years after the last participant is randomized|The proportion of participants with serious adverse events (SAEs), Up to 5 years after the last participant is randomized|Maximum observed concentration (Cmax) of transgene level, Up to 5 years after the last participant is randomized|Time of maximum observed plasma concentration (Tmax) of transgene level, Up to 5 years after the last participant is randomized|Area under the concentration-time curve (AUC) of transgene level, Up to 5 years after the last participant is randomized|Changes from baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30 items (QLQ-C30) primary domains, EORTC QLQ-C30 primary domains: fatigue, pain, physical functioning, role functioning, cognitive functioning, and global health status/quality of life (QoL)., Up to 5 years after the last participant is randomized|Changes from baseline in EORTC Quality of Life Multiple Myeloma Module- 20 items (QLQ-MY20) primary domains, EORTC QLQ-MY20 primary domains: disease symptoms and side effects of treatment, Up to 5 years after the last participant is randomized|Time to meaningful improvement in EORTC QLQ-C30 global health status/QoL., Up to 5 years after the last participant is randomized
The purpose of this study is to compare the efficacy and safety of BMS-986393 versus standard regimens in adult participants with Relapsed or Refractory and Lanalidomide-refractory Multiple Myeloma.